Delphi Behavioral Health Group, a prominent provider in the substance use disorder treatment field, has named Michael Borkowski as its new Chief Executive Officer. Borkowski, who joined Delphi in 2016 as Chief Financial Officer, brings a robust background in finance and leadership to the role. As a certified public accountant with a bachelor’s degree in accounting and finance from Florida State University, he combines financial expertise with deep organizational knowledge. He succeeds former CEO Matthew Feehery and now faces the critical task of expanding Delphi’s clinical strategies, driving addiction treatment facility growth, scaling its treatment facilities, and broadening its geographic footprint in an increasingly competitive behavioral health market.
A Proven Leader with a Strategic Vision
Michael Borkowski’s appointment comes at a crucial time for Delphi Behavioral Health Group, which has steadily grown since its inception in 2016. Reflecting on the organization’s journey, Borkowski remarked, “Although we operate in a constantly evolving environment, I strongly believe that the company has prioritized providing top-notch care and support for its clients and their families since its inception six years ago.” His confidence in Delphi’s foundation and team demonstrates a clear commitment to advancing the company’s mission while navigating the challenges and opportunities ahead.
With a keen focus on integrating clinical excellence with sustainable business growth, Borkowski aims to leverage his financial and operational expertise to refine Delphi’s clinical programs and enhance patient outcomes. Under his leadership, Delphi plans to not only increase its number of facilities but also improve the quality and breadth of care available to patients battling substance use disorders — driving meaningful addiction treatment facility growth.
Expanding Reach Across Multiple States
Delphi Behavioral Health Group is headquartered in Fort Lauderdale, Florida, and currently operates 14 treatment centers spread across five states. Its comprehensive continuum of care includes detoxification services, inpatient treatment, intensive outpatient programs, and partial hospitalization. The provider addresses a wide range of substance use disorders, including alcohol, opioids, stimulants, sedatives, and benzodiazepines.
A key element of Delphi’s success is its partnerships with major insurance carriers, such as Cigna, Aetna, Elevance Health, and CareFirst BlueChoice. These collaborations ensure patients have access to high-quality care without prohibitive financial barriers, supporting Delphi’s mission to make effective treatment accessible and continuing the momentum of addiction treatment facility growth.
Financial Backing and Strategic Mergers Fuel Growth
Delphi’s trajectory of growth has been bolstered by strategic financial moves and mergers. In 2017, The Halifax Group, a private equity firm specializing in lower middle-market businesses valued between $50 million and $250 million, recapitalized Delphi, acquiring a majority stake in the organization. This investment provided the resources and strategic guidance needed for expansion.
In 2018, Delphi merged with Summit Behavioral Health, a New Jersey-based addiction treatment provider. While the financial terms were not disclosed, this merger expanded Delphi’s footprint and diversified its service offerings, reinforcing its presence in the Northeast. These moves have been critical drivers of addiction treatment facility growth for Delphi.
These moves reflect broader industry trends where private equity interest in the substance use disorder treatment space is intensifying. According to M&A advisory firm The Braff Group, the period between 2017 and 2021 saw 300 deals in this behavioral health subsector—the highest volume across all behavioral health categories. Delphi’s strategic positioning amid this activity highlights its potential to continue capitalizing on market opportunities and further accelerate addiction treatment facility growth.
Addressing Industry Challenges: Staffing and Reimbursement
While Delphi is well-positioned for growth, several industry-wide challenges loom large. Staffing shortages continue to strain behavioral health providers nationwide, with competition for qualified clinicians intensifying. Ensuring a skilled and stable workforce is critical to maintaining high-quality care and expanding capacity.
Additionally, fluctuating reimbursement rates from insurers and government programs add financial uncertainty to the mix. Navigating these reimbursement complexities requires strong financial stewardship and innovative operational strategies, areas where Borkowski’s background will be particularly valuable as he drives addiction treatment facility growth despite these headwinds.
Delphi’s Chairman of the Board, Mike Katz, praised Borkowski’s qualifications and outlook: “Michael’s extensive background in executive leadership and financial operations make him an ideal fit for this role. He is a proven leader, and I am confident that his strategic focus will help drive both growth and profitability for the company.” With this guidance, Delphi is poised for continued addiction treatment facility growth.
Looking Ahead: A Commitment to Comprehensive Care
As Michael Borkowski assumes the CEO role, Delphi Behavioral Health Group enters a new chapter focused on growth, innovation, and clinical excellence. By expanding treatment offerings, increasing geographic reach, and strengthening insurer relationships, Delphi aims to better serve individuals and families affected by substance use disorders. This commitment directly supports ongoing addiction treatment facility growth.
In a behavioral health landscape marked by rapid change and increasing demand, Borkowski’s leadership comes at a critical time. With a dedicated team and strong financial foundation, Delphi is poised to advance its mission of delivering compassionate, effective treatment to those in need—helping more patients on their journey to recovery and fueling its vision for sustained addiction treatment facility growth.
